Gemini Therapeutics

What Gemini Therapeutics does

Gemini Therapeutics is a Cambridge, Massachusetts-based, clinical-stage biopharmaceutical company founded in 2015 that develops therapeutics for genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. According to firmographic data, the company pursued a precision-medicine approach, stratifying patients by genetic variants to inform therapeutic intervention in complement-mediated retinal disease. It was publicly listed on NASDAQ under ticker GMTX via the 2020 acquisition of SPAC FS Development Corp, and is now in delisted status with a small operating team of 11–50 employees.

Gemini Therapeutics raised approximately $139.5 million across three disclosed equity rounds between 2016 and 2021, anchored by a deep syndicate of healthcare-focused venture investors including Atlas Venture, Lightstone Ventures, OrbiMed, Foresite Capital (lead on the largest round), Fidelity, Boxer Capital, Acorn Bioventures, Alyeska, Dafna, Suvretta Capital, Wellington Management, and Wu Capital. The company is led by a named CEO and a scientific co-founder, with a president/CEO and a chief medical officer in the leadership roster. No commercial products, revenue, pricing models, or distribution channels are disclosed in the input data, consistent with a clinical-stage posture.

The input data exhibits material internal inconsistency: while firmographic and funding sources describe an ophthalmology / rare-disease biotech, a separate product-and-technology block attributes to Gemini Therapeutics an albumin-binding prodrug of doxorubicin (aldoxorubicin) and oncology indications (soft tissue sarcoma, Kaposi's sarcoma) with ASCO 2026 data presentations. This contradicts the AMD focus and the public GMTX corporate history. The investment analysis above is anchored on the consistent firmographic, funding, leadership, and corporate-action evidence; the oncology product block is treated as a likely data-attribution error and is not relied upon for the analytical conclusions.

Name

Gemini Therapeutics

Legal name

Gemini Therapeutics

Website

https://geminitherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Gemini Therapeutics is a Cambridge, Massachusetts-based clinical-stage biopharma (now delisted from NASDAQ as GMTX) developing genetically-targeted therapeutics for dry age-related macular degeneration and associated rare genetic diseases.

Ownership category

akta.pro rank

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Gemini Therapeutics is developing aldoxorubicin, an albumin-binding prodrug of doxorubicin designed for tumor-targeted delivery via albumin receptor-mediated uptake. The asset is being advanced in soft tissue sarcoma and Kaposi's sarcoma, with integrated analyses presented at ASCO 2026 demonstrating up to ~10-fold higher intratumoral doxorubicin-equivalent exposure and a superior cardiac safety profile versus conventional doxorubicin.

Product overview

Gemini Therapeutics is a clinical-stage oncology company developing aldoxorubicin, an albumin-binding prodrug of doxorubicin. The company's single-lead product leverages tumor-targeted delivery technology to improve the safety and efficacy profile of conventional doxorubicin chemotherapy. Gemini Therapeutics presented integrated analyses at ASCO 2026 demonstrating aldoxorubicin's superior cardiac safety profile in soft tissue sarcoma patients and enhanced intratumoral drug delivery in Kaposi's sarcoma.

Differentiator

Problem solved

Functional benefit

Products and services

• Aldoxorubicin Albumin-binding prodrug of doxorubicin designed for tumor-targeted delivery via albumin receptor-mediated uptake. In clinical development for soft tissue sarcoma and Kaposi's sarcoma, with demonstrated improved cardiac safety profile (smaller LVEF declines, fewer heart-failure-related adverse events) and higher intratumoral drug exposure compared to conventional doxorubicin. Targeted at oncology patients with doxorubicin-eligible sarcomas.

Quantifiable outcome

• Smaller mean LVEF declines: -3.17 vs -5.77 percentage points (aldxorubicin vs conventional doxorubicin)
• +4 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves1 record

Expansion highlights3 records

Broad incumbents

• Roche: Roche markets Lucentis and Vabysmo for retinal disease and has invested heavily in dry AMD pipeline programs, positioning it as a broad incumbent against which any AMD biotech must compete.
• Regeneron Pharmaceuticals: Regeneron markets Eylea (aflibercept), the leading anti-VEGF therapy for wet AMD and a dominant force in retinal disease — establishing the standard-of-care competitive frame within which any new dry AMD entrant must differentiate.

Direct peers

• Apellis Pharmaceuticals: Apellis develops complement-pathway inhibitors (pegcetacoplan / Syfovre, Empaveli) for geographic atrophy / dry AMD and other complement-mediated diseases, making it a direct therapeutic-area and mechanistic competitor to Gemini Therapeutics' complement-pathway / dry AMD focus.
• Iveric Bio (Astellas): Iveric Bio (acquired by Astellas in 2023) developed Izervay (avacincaptad pegol), a complement C5 inhibitor for geographic atrophy — a directly competitive complement-pathway program in dry AMD and the most analogous asset to Gemini's therapeutic approach.
• Annexon Biosciences: Annexon is a clinical-stage complement-pathway company developing classical-complement inhibitors for geographic atrophy and other complement-mediated diseases, overlapping directly with Gemini's mechanistic and indication focus.
• Gyroscope Therapeutics (Novartis): Gyroscope (acquired by Novartis in 2021) developed GT005, a gene therapy for geographic atrophy / dry AMD with a genetically defined patient-stratification strategy — closely paralleling Gemini's genetically defined dry AMD positioning.

Emerging players

• Adverum Biotechnologies: Adverum is developing intravitreal gene therapies for wet AMD and other retinal diseases, intersecting with Gemini's genetically defined ophthalmology niche through novel ocular delivery and complement-pathway-adjacent approaches.
• Alnylam Pharmaceuticals: Alnylam is a leading RNA-interference therapeutics company focused on rare genetic diseases — overlapping with Gemini's positioning in rare genetic ophthalmic and systemic indications using a nucleic-acid-based therapeutic modality.
• BioMarin Pharmaceutical: BioMarin is a rare-disease biotech with a track record of developing recombinant-protein therapeutics (e.g., enzyme replacement therapies), comparable in scale, modality, and genetically defined patient-stratification approach to Gemini's therapeutic platform.

Others

• Disc Medicine: Disc Medicine acquired Gemini Therapeutics' assets/program in a reverse-merger transaction, making it the corporate successor and most direct comparator for the value ultimately realized from Gemini's pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/gemini_thera

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gemini Therapeutics